SCHEMBL5347491

SCHEMBL5347491

O=C(Nc1cccc(N2CCN(c3ccccn3)CC2)n1)Nc1csc(-c2ccccc2)n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 8/20 0.71
CDK5R1 Q15078 8/20 0.71
CCNA2 P20248 3/20 0.53
CDK2 P24941 3/20 0.53
CCNA1 P78396 3/20 0.53
MAPK1 P28482 2/20 0.47
LMNA P02545 2/20 0.47
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 1/20 0.46
SLC6A7 Q99884 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KDM6B O15054 1/20 0.44
DYRK1A Q13627 1/20 0.44
CNR1 P21554 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5345136 0.95 CDK5 (0.80) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5338211 0.93 CDK5 (0.70) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5341693 0.87 CDK5 (0.80) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5342681 0.86 CDK5 (0.69) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5692115 0.83 CDK5 (1.00) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5345330 0.83 CDK5 (0.74) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5690422 0.83 CDK5 (0.81) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5347774 0.81 CDK5 (0.78) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5347393 0.81 CDK5 (0.78) CDK5CDK5R1CCNA2CDK2CCNA1
SCHEMBL5348793 0.81 CDK5 (0.80) CDK5CDK5R1CCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
EP-1483263-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2004-12-08 EP disclosed
US-20040044044-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-03-04 US disclosed
US-20040039029-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-02-26 US disclosed
US-6645990-B2 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases AMGEN INC. 2003-11-11 US disclosed
WO-2003070727-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2003-08-28 WO disclosed
US-20020193405-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193405-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX CDK5 64/4885CDK5R1 359/4885CCNA2 765/4885
US-20040039029-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX CDK5 64/4885CDK5R1 359/4885CCNA2 765/4885
US-20040044044-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX CDK5 64/4885CDK5R1 359/4885CCNA2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.